Citation: | Qiuyan Xia, Jiajia Jiang, Wei Zhao, Qi Tang, Xiaohua Li, Tengqi Wang, Yan Zhou. Epiregulin promotes growth and metastasis of gastric cancer via the ERK/JNK/p38 signaling pathway[J]. Blood&Genomics, 2021, 5(2): 135-145. doi: 10.46701/BG.2021022021125 |
[1] |
Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635−648. doi: 10.1016/S0140-6736(20)31288-5
|
[2] |
Zong L, Abe M, Seto Y, et al. The challenge of screening for early gastric cancer in China[J]. Lancet, 2016, 388(10060): 2606. doi: 10.1016/S0140-6736(16)32226-7
|
[3] |
Das M. Neoadjuvant chemotherapy: survival benefit in gastric cancer[J]. Lancet Oncol, 2017, 18(6): e307. doi: 10.1016/S1470-2045(17)30321-2
|
[4] |
Ilson DH. Targeting the vascular endothelial growth factor pathway in gastric cancer: a hit or a miss?[J]. J Clin Oncol, 2016, 34(13): 1431−1432. doi: 10.1200/JCO.2015.65.8666
|
[5] |
Burki TK. Progression-free survival with regorafenib in gastric cancer[J]. Lancet Oncol, 2016, 17(8): e323. doi: 10.1016/S1470-2045(16)30284-4
|
[6] |
Aoyama T, Nishikawa K, Fujitani K, et al. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer[J]. Ann Oncol, 2017, 28(8): 1876−1881. doi: 10.1093/annonc/mdx236
|
[7] |
Alsina M, Gullo I, Carneiro F. Intratumoral heterogeneity in gastric cancer: a new challenge to face[J]. Ann Oncol, 2017, 28(5): 912−913. doi: 10.1093/annonc/mdx134
|
[8] |
Röcken C. Molecular classification of gastric cancer[J]. Expert Rev Mol Diagn, 2017, 17(3): 293−301. doi: 10.1080/14737159.2017.1286985
|
[9] |
Amon. Antibody improves survival in gastric cancer[J]. Cancer Discovery, 2016, 6(8): OF8. doi: 10.1158/2159-8290.CD-NB2016-077
|
[10] |
Martin LJ, Smith SB, Khoutorsky A, et al. Epiregulin and EGFR interactions are involved in pain processing[J]. J Clin Invest, 2017, 127(9): 3353−3366. doi: 10.1172/JCI87406
|
[11] |
Pradhan SA, Rather MI, Tiwari A, et al. Evidence that TSC2 acts as a transcription factor and binds to and represses the promoter of Epiregulin[J]. Nucleic Acids Res, 2014, 42(10): 6243−6255. doi: 10.1093/nar/gku278
|
[12] |
Xu X, Chen W, Leng S, et al. Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop[J]. Carcinogenesis, 2017, 38(6): 604−614. doi: 10.1093/carcin/bgx039
|
[13] |
Kohsaka S, Hinohara K, Wang L, et al. Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma[J]. Neuro Oncol, 2014, 16(7): 960−970. doi: 10.1093/neuonc/not315
|
[14] |
Rizzi M, Pittarella P, Sabbatini M, et al. Epiregulin induces human SK-N-BE cell differentiation through ERK1/2 signaling pathway[J]. Growth Factors, 2013, 31(3): 90−97. doi: 10.3109/08977194.2013.795958
|
[15] |
Neufert C, Becker C, Türeci Ö, et al. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK[J]. J Clin Invest, 2013, 123(4): 1428−1443. doi: 10.1172/JCI63748
|
[16] |
Cao Y, Xia DS, Qi SR, et al. Epiregulin can promote proliferation of stem cells from the dental apical papilla via MEK/Erk and JNK signalling pathways[J]. Cell Prolif, 2013, 46(4): 447−456. doi: 10.1111/cpr.12039
|
[17] |
Llovet P, Sastre J, Ortega JS, et al. Prognostic value of BRAF, PI3K, PTEN, EGFR copy number, amphiregulin and epiregulin status in patients with KRAS codon 12 wild-type metastatic colorectal cancer receiving first-line chemotherapy with anti-EGFR therapy[J]. Mol Diagn Ther, 2015, 19(6): 397−408. doi: 10.1007/s40291-015-0165-0
|
[18] |
Takahashi N, Yamada Y, Furuta K, et al. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer[J]. Br J Cancer, 2014, 110(11): 2716−2727. doi: 10.1038/bjc.2014.230
|
[19] |
Fan J bo, Liu W, Zhu X hui, et al. EGFR-AKT-mTOR activation mediates epiregulin-induced pleiotropic functions in cultured osteoblasts[J]. Mol Cell Biochem, 2015, 398(1–2): 105−113. doi: 10.1007/s11010-014-2210-4
|
[20] |
Zhao W, Jia L, kuai X, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer[J]. Cancer Med, 2019, 8(3): 1135−1147. doi: 10.1002/cam4.1934
|
[21] |
F W, HQ Y, BS H, et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway[J]. Oncotarget, 2015, 6(10): 7899−7917. doi: 10.18632/oncotarget.3219
|
[22] |
Seligmann JF, Elliott F, Richman SD, et al. Combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with RAS wild-type[J]. JAMA Oncol, 2016, 2(5): 633−642. doi: 10.1001/jamaoncol.2015.6065
|
[23] |
Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab[J]. J Clin Oncol, 2009, 27(30): 5068−5074. doi: 10.1200/JCO.2008.21.3744
|
[24] |
Takahashi M, Hayashi K, Yoshida K, et al. Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells[J]. Circulation, 2003, 108(20): 2524−2529. doi: 10.1161/01.CIR.0000096482.02567.8C
|
[25] |
Homma T, Kato A, Sakashita M, et al. Potential involvement of the epidermal growth factor receptor ligand epiregulin and matrix metalloproteinase-1 in pathogenesis of chronic rhinosinusitis[J]. Am J Respir Cell Mol Biol, 2017, 57(3): 334−345. doi: 10.1165/rcmb.2016-0325OC
|
[26] |
Q Xia, Y Zhou, H Y, et al. Elevated epiregulin expression predicts poor prognosis in gastric cancer[J]. Pathol Res Pract, 2019, 215(5): 873−879. doi: 10.1016/j.prp.2019.01.030
|
[27] |
Ornskov D, Nexo E, Sorensen BS. Insulin induces a transcriptional activation of epiregulin, HB-EGF and amphiregulin, by a PI3K-dependent mechanism: Identification of a specific insulin-responsive promoter element[J]. Biochem Biophys Res Commun, 2007, 354(4): 885−891. doi: 10.1016/j.bbrc.2007.01.047
|
[28] |
Zhuang S, Yan Y, Daubert RA, et al. Epiregulin promotes proliferation and migration of renal proximal tubular cells[J]. Am J Physiol Ren Physiol, 2007, 293(1): F219−226. doi: 10.1152/ajprenal.00082.2007
|
[29] |
Hu K, Li S lin, Gan Y hua, et al. Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt[J]. Oral Oncol, 2009, 45(2): 156−163. doi: 10.1016/j.oraloncology.2008.04.009
|
[30] |
Tripathi SC, Fahrmann JF, Celiktas M, et al. MCAM mediates chemoresistance in small-cell lung cancer via the PI3K/AKT/SOX2 signaling pathway[J]. Cancer Res, 2017, 77(16): 4414−4425. doi: 10.1158/0008-5472.CAN-16-2874
|
[31] |
Riese DJ, Cullum RL. Epiregulin: roles in normal physiology and cancer[J]. Semin Cell Dev Biol, 2014, 28: 49−56. doi: 10.1016/j.semcdb.2014.03.005
|
[32] |
Farooqui M, Bohrer LR, Brady NJ, et al. Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival[J]. Mol Cancer, 2015, 14(1): 138. doi: 10.1186/s12943-015-0408-z
|
[33] |
Boyles JS, Atwell S, Druzina Z, et al. Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody[J]. Protein Sci, 2016, 25(11): 2028−2036. doi: 10.1002/pro.3023
|
[34] |
Iijima M, Anai M, Kodama T, et al. Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling[J]. Biochem Biophys Res Commun, 2017, 489(1): 83−88. doi: 10.1016/j.bbrc.2017.03.006
|
[35] |
Belda BJ, Thompson JT, Sinha R, et al. The dietary fatty acid 10E12Z-CLA induces epiregulin expression through COX-2 dependent PGF2α synthesis in adipocytes[J]. Prostaglandins Other Lipid Mediat, 2012, 99(1–2): 30−37. doi: 10.1016/j.prostaglandins.2012.05.001
|
[36] |
Liu S, Ye D, Xu D, et al. Autocrine epiregulin activates EGFR pathway for lung metastasis via EMT in salivary adenoid cystic carcinoma[J]. Oncotarget, 2016, 7(18): 25251−25263. doi: 10.18632/oncotarget.7940
|
[37] |
Cho MC, Choi HS, Lee S, et al. Epiregulin expression by Ets-1 and ERK signaling pathway in Ki-ras-transformed cells[J]. Biochem Biophys Res Commun, 2008, 377(3): 832−837. doi: 10.1016/j.bbrc.2008.10.053
|
[38] |
Singh B, Bogatcheva G, Washington MK, et al. Transformation of polarized epithelial cells by apical mistrafficking of epiregulin[J]. Proc Natl Acad Sci U S A, 2013, 110(22): 8960−8965. doi: 10.1073/pnas.1305508110
|
[39] |
Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab[J]. J Clin Oncol, 2007, 25(22): 3230−3237. doi: 10.1200/JCO.2006.10.5437
|